CARB-X funds Tetraphase Pharmaceuticals antibiotic research with $4M

CARB-X funds Tetraphase Pharmaceuticals antibiotic research with $4M

March 31, 2017 Off By Dino Mustafić

Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), an international, public-private partnership focused on the discovery and development of new antimicrobial products to address the threat of antibiotic resistance, will fund research of Tetraphase Pharmaceuticals’s pipeline candidate TP-6076, a novel, synthetic, fluorocycline antibiotic candidate with $4 million.

Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, said that in preclinical research, TP-6076 has demonstrated potent activity against MDR bacteria, particularly those considered to be urgent or serious threats by the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).

“The selection of TP-6076 as one of the first candidates in the CARB-X portfolio highlights the potential of this early stage antibiotic compound due to its exceptional in vitro potency against two of the most dangerous organisms, carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Acinetobacter baumannii (CRAB),” said Guy Macdonald, President and CEO of Tetraphase. ”

CARB-X was launched in July 2016 and represents the world’s largest public-private funding initiative to accelerate the research and development of novel drugs, diagnostics and vaccines to protect human health from the most serious bacterial threats.  Companies with early stage projects were selected through a rigorous application process identifying programs that target one of the deadly antibiotic-resistant bacteria on the Serious or Urgent Threat List prepared by the CDC or on the Priority Pathogens list published by the WHO